Research and Practice in Thrombosis and Haemostasis最新文献

{"title":"Altered clot structure in pregnant women who will develop postpartum hemorrhage","authors":"Claire de Moreuil , Brigitte Pan-Petesch , François Anouilh , Dino Mehic , Theresa Schramm , Christoph Friedl , Alisa S. Wolberg , Francis Couturaud , Johanna Gebhart , Cihan Ay , Ingrid Pabinger","doi":"10.1016/j.rpth.2025.102683","DOIUrl":"10.1016/j.rpth.2025.102683","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102683"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143350259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mini-clusters of postadenovirus VITT","authors":"Michele P. Lambert , Theodore E. Warkentin","doi":"10.1016/j.rpth.2024.102641","DOIUrl":"10.1016/j.rpth.2024.102641","url":null,"abstract":"","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102641"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired factor V inhibitor in a case of pediatric venous thrombosis","authors":"Sweta Gupta ,&nbsp;Matthew W. Bunce ,&nbsp;Emily A. Cid ,&nbsp;Rodney M. Camire ,&nbsp;Amy D. Shapiro","doi":"10.1016/j.rpth.2024.102646","DOIUrl":"10.1016/j.rpth.2024.102646","url":null,"abstract":"<div><h3>Background</h3><div>The development of acquired factor (F)V with inhibitor (AFVwI) is rare, resulting mainly in bleeding complications, although sporadic cases of thrombosis in adults have been reported.</div></div><div><h3>Key Clinical Question</h3><div>How do you diagnose and manage a pediatric case of acute deep venous thrombosis associated with the concurrent finding of AFVwI?</div></div><div><h3>Clinical Approach</h3><div>A 13-year-old female with Crohn's Disease and May–Thurner anatomy developed extensive deep venous thrombosis of the left lower extremity, complicated by the finding of AFVwI, discovered during the evaluation of a prolonged prothrombin time and a low FV activity. Anticoagulation was initiated with low-molecular-weight heparin followed by a direct oral anticoagulant, rivaroxaban, without any complications. AFVwI was undetectable after 5 months with normalization of FV activity.</div></div><div><h3>Conclusion</h3><div>Our case highlights the first pediatric case of thrombosis with a rare finding of AFVwI, successfully managed with anticoagulation therapy with complete resolution.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102646"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extending health equity to people with moderate and mild hemophilia A: revisiting the HAVEN 6 trial","authors":"Cedric Hermans ,&nbsp;Michiel Coppens ,&nbsp;Giuliana Ventriglia ,&nbsp;Gavin Ling ,&nbsp;Michaela Lehle ,&nbsp;Steven W. Pipe","doi":"10.1016/j.rpth.2024.102648","DOIUrl":"10.1016/j.rpth.2024.102648","url":null,"abstract":"<div><div>Congenital hemophilia A (HA) disease severity has traditionally been categorized according to intrinsic factor (F)VIII levels, with &lt;1% of normal indicating severe HA, 1% to 5% moderate HA, and 6% to 40% mild HA. However, mounting evidence illustrates considerable variability in bleeding phenotype regardless of FVIII level. Despite treatment advances, people with moderate or mild HA may be neglected, as treatment guidelines and established norms focus on FVIII levels, and many clinical trials do not include people with FVIII &gt; 1%. Data from the HAVEN 6 trial demonstrated that people with moderate or mild HA, for whom prophylaxis was warranted by the treating physician’s judgment, experienced a clear clinical benefit from receiving emicizumab prophylaxis. A shift in treatment paradigms to incorporate clinical phenotypes alongside FVIII levels should be encouraged. This change in practice would allow treaters to extend health equity to people with moderate or mild HA.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102648"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific cut-off for dilute Russell’s viper venom time lupus anticoagulant test may be of value","authors":"Ning Tang ,&nbsp;Yuanmei Luo ,&nbsp;Mangui Li ,&nbsp;Mingchao Zhu ,&nbsp;Dengju Li","doi":"10.1016/j.rpth.2024.102657","DOIUrl":"10.1016/j.rpth.2024.102657","url":null,"abstract":"<div><h3>Background</h3><div>Current guidelines recommend application of the 99th percentile to determine the cut-off value on at least 120 healthy donors regardless of sex for lupus anticoagulant (LA) ratio of each step. However, a statistically significant difference between the sexes has been found for LA ratio recently.</div></div><div><h3>Objectives</h3><div>To clarify whether this sex difference in dilute Russell’s viper venom time (DRVVT) exists in various detection systems and the necessity of setting sex-specific cut-off values.</div></div><div><h3>Methods</h3><div>Blood samples from healthy donors were detected on 3 DRVVT detection systems, and the sex-specific cut-offs of DRVVT test were obtained based on the 99th or 97.5th centile of screen, confirm, and normalized ratios (NRs) grouped by sex in each system. One thousand one hundred twenty one female patients with suspected antiphospholipid syndrome (APS) were retrospectively investigated, the APS-associated clinical and laboratory characteristics of female patients stratified by different cut-offs of DRVVT ratio were compared.</div></div><div><h3>Results</h3><div>The DRVVT NRs of females were significantly lower than those of males on each system. The female patients with DRVVT NR between female-specific and regardless of sex cut-offs had higher positive rates of silica clotting time test and LA retest results after 12 weeks than those with DRVVT NRs lower than female-specific cut-off, there were also more patients who met the APS clinical criteria.</div></div><div><h3>Conclusion</h3><div>The sex difference of the cut-off value for DRVVT LA test is confirmed on multiple systems, the female-specific cut-off is lower than regardless of sex cut-off and may lead to more female patients being considered as high-risk population for APS.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102657"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11741938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occurrence and management of thrombosis recurrence and bleeding in low-molecular-weight heparin-treated patients with cancer-associated thrombosis: a French nationwide cohort study","authors":"Isabelle Mahé ,&nbsp;Gaelle Gusto ,&nbsp;Nadia Quignot ,&nbsp;Artak Khachatryan ,&nbsp;Jose Chaves ,&nbsp;Audrey Moniot ,&nbsp;Lucas Andre ,&nbsp;Sylvain Van Roy ,&nbsp;Ruth Mokgokong ,&nbsp;Laurent Bertoletti","doi":"10.1016/j.rpth.2024.102642","DOIUrl":"10.1016/j.rpth.2024.102642","url":null,"abstract":"<div><h3>Background</h3><div>Rates of venous thromboembolism (VTE) recurrence and bleeding remain high in patients with cancer who are prescribed anticoagulants (ACs) such as low-molecular-weight heparin (LMWH) after an initial VTE event.</div></div><div><h3>Objectives</h3><div>To identify patient characteristics associated with VTE recurrence and bleeding in patients receiving LMWH for cancer-associated VTE and to explore secondary AC management and clinical outcomes in these patients.</div></div><div><h3>Methods</h3><div>An observational study was conducted using nationwide French data for adults with active cancer who were hospitalized with VTE in 2013-2018 and were reimbursed for LMWH ≤ 30 days after hospital discharge. The main outcomes were VTE recurrence and bleeding. For both outcomes, the proportions of patients who experienced the outcome were calculated for different patient characteristics. AC switching following VTE recurrence and bleeding was tracked using Anatomical Therapeutic Chemical codes.</div></div><div><h3>Results</h3><div>A total of 31,771 patients received LMWH, of whom 1925 (6.1%) experienced VTE recurrence and 1804 (5.7%) bleeding. Most recurrent VTE and bleeding events occurred within 6 months after the initial VTE event. The proportion of patients with VTE recurrence and bleeding varied between cancer types. Most patients who experienced VTE recurrence or bleeding continued to receive LMWH. Eleven percent of patients with VTE recurrence experienced a further recurrent VTE event within 3 months.</div></div><div><h3>Conclusion</h3><div>More than 10% of patients who received LMWH for cancer-associated VTE experienced VTE recurrence or bleeding. AC management options in this patient population should be prospectively assessed in clinical trials.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102642"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia","authors":"Robert H. Lee,&nbsp;Abigail Ballard-Kordeliski,&nbsp;Summer R. Jones,&nbsp;Wolfgang Bergmeier","doi":"10.1016/j.rpth.2024.102672","DOIUrl":"10.1016/j.rpth.2024.102672","url":null,"abstract":"<div><h3>Background</h3><div>Antiplatelet therapy (APT), mainly aspirin and P2Y12 receptor inhibitors, reduces the incidence of recurrent arterial thrombosis but also increases bleeding risk. Therefore, management of APT in patients with thrombocytopenia, itself an independent risk factor for bleeding, is a clinical challenge with few evidence-based guidelines. Data are lacking on the combined impact of thrombocytopenia and APT on hemostasis.</div></div><div><h3>Objectives</h3><div>To systematically investigate the combined effect of thrombocytopenia and APT in mouse models of hemostasis and thrombosis.</div></div><div><h3>Methods</h3><div>Platelet-depleted mice were repleted with donor platelets inhibited with aspirin and/or clopidogrel at low (&lt;1 × 10⁸/mL) or normal (&gt;2) platelet counts. Hemostasis was assessed in the saphenous vein laser injury model, and thrombosis was assessed in the carotid artery ferric chloride model.</div></div><div><h3>Results</h3><div>In the saphenous vein laser injury model, neither single nor dual APT significantly increased bleeding compared with vehicle at platelet counts &gt;2 × 10⁸/mL. However, for platelet counts &lt;1, clopidogrel prolonged the time to the first hemostatic plug, and dual APT prolonged the time to the first plug and total bleeding time compared with vehicle and aspirin treatment. In the carotid artery ferric chloride thrombosis model, clopidogrel was entirely protected against platelet-rich thrombus formation, while aspirin had minimal effect.</div></div><div><h3>Conclusion</h3><div>Our experimental data suggests that for severe thrombocytopenia, single APT provides an appropriate balance of antithrombotic effect and limited bleeding, with clopidogrel demonstrating a greater antithrombotic effect but slightly increased bleeding compared with aspirin.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102672"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analyses of the hemostatic efficacy and surgical device performance of powdered oxidized regenerated cellulose and starch-based powder formulations","authors":"Marianne Stark,&nbsp;Allen Y. Wang,&nbsp;Brittny Corrigan,&nbsp;Henok G. Woldu,&nbsp;Samar Azizighannad,&nbsp;Gustavo Cipolla,&nbsp;Richard Kocharian,&nbsp;Hector De Leon","doi":"10.1016/j.rpth.2024.102668","DOIUrl":"10.1016/j.rpth.2024.102668","url":null,"abstract":"<div><h3>Background</h3><div>Hemostatic powders offer unique therapeutic advantages over other formulations, including ease of application and rapid distribution over large bleeding surfaces. The efficacy of powder-based hemostats is dependent on device performance, which is rarely investigated independently from efficacy.</div></div><div><h3>Objectives</h3><div>The current study aimed to compare the hemostatic efficacy of an oxidized regenerated cellulose agent (Surgicel, Ethicon, Inc) and 3 starch-based biopolymers (Arista, Becton Dickinson; PerClot, Baxter International; and 4DryField, PlantTec Medical GmbH) and the performance of their delivery device applicators.</div></div><div><h3>Methods</h3><div>Efficacy was evaluated in a porcine model of bleeding using 2 study designs where the powder was delivered with (experiment 1) and without (experiment 2) device applicators. Device performance (powder expression) was examined <em>in vitro</em> at 3 device positions/angles: 90° (vertical, downward), 45° (slanted, downward), and 180° (horizontal).</div></div><div><h3>Results</h3><div>Surgicel efficacy rate was noninferior (<em>P</em> ≤ .0002) and superior (<em>P</em> ≤ .004) to that of any of the 3 starch-based agents regardless of whether the powder was delivered with their devices (experiment 1) or directly applied onto the bleeding sites (experiment 2). Surgicel required fewer applications (<em>P</em> ≤ .0002) and less powder (<em>P</em> &lt; .0001) to achieve hemostasis. The Surgicel device was the only one that consistently delivered precise amounts of powder over a critical range of applications in the 3 positions tested.</div></div><div><h3>Conclusion</h3><div>The oxidized regenerated cellulose powder was the most efficacious hemostat, and the Surgicel applicator exhibited the highest performance compared with any of the 3 starch-based devices investigated. The current study highlights the relevance of combining high-efficacy powder hemostats with innovative, high-performance applicators to effectively manage bleeding control in surgical settings.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102668"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of anti–platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic","authors":"Nicolas Gendron ,&nbsp;Dominique Helley ,&nbsp;Johannes Thaler ,&nbsp;Dorothée Faille ,&nbsp;Christine Le Beller ,&nbsp;Maxime Gruest ,&nbsp;Jérôme Hadjadj ,&nbsp;Aurélien Philippe ,&nbsp;Faris Zeco ,&nbsp;Marie Courbebaisse ,&nbsp;Luc Darnige ,&nbsp;Wafa Amara ,&nbsp;Leyla Calmette ,&nbsp;Beatrice Parfait ,&nbsp;Claire Auditeau ,&nbsp;Richard Chocron ,&nbsp;Lina Khider ,&nbsp;Laetitia Mauge ,&nbsp;Olivier Espitia ,&nbsp;Gérard Friedlander ,&nbsp;David M. Smadja","doi":"10.1016/j.rpth.2025.102701","DOIUrl":"10.1016/j.rpth.2025.102701","url":null,"abstract":"<div><h3>Background</h3><div>The increased interest in anti–platelet factor 4 (PF4)–heparin complex (anti-PF4/H) antibodies following the COVID-19 pandemic has established them as crucial players in immunothrombosis.</div></div><div><h3>Objectives</h3><div>We aimed to investigate the involvement of anti-PF4/H antibodies during COVID-19 and after vaccination, particularly in patients with systemic inflammatory disease (SID).</div></div><div><h3>Methods</h3><div>This retrospective study analyzed the presence of anti-PF4/H antibodies and their ability to induce platelet activation in COVID-19 patients with and without suspected heparin-induced thrombocytopenia (HIT), vaccine-induced immune thrombotic thrombocytopenia (VITT) patients, and in controls and SID patients following COVID-19 vaccination.</div></div><div><h3>Results</h3><div>No significant increase in anti-PF4/H antibody levels was observed during COVID-19 regardless of disease severity. Despite a 2-fold increase in HIT suspicion observed during the pandemic, there was no corresponding increase in HIT diagnoses. Additionally, no significant increase in anti-PF4/H levels was noted after vaccination, even in SID patients. None of the positive anti-PF4/H antibodies detected in COVID-19 or vaccination cohorts induced platelet activation, measured by soluble P-selectin levels and flow cytometry-based on platelet microvesicle generation. Finally, in VITT patients, unlike in HIT patients, anti-PF4/H levels were strongly associated with platelet microvesicle assay and moderately with soluble P-selectin levels.</div></div><div><h3>Conclusion</h3><div>Our study found no significant increase in anti-PF4/H antibodies in COVID-19 or after vaccination, including in SID patients. However, in VITT patients, but not in HIT patients, these antibodies were correlated with platelet activation. This finding suggests that anti-PF4/H antibodies play a different role in the pathophysiology of VITT but that their interest is limited outside clear contexts of HIT/VITT suspicion.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102701"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trenonacog alfa safety, efficacy, and pharmacokinetics in previously treated pediatric hemophilia B","authors":"Kateryna Vilchevska ,&nbsp;Can Balkan ,&nbsp;Valentin Turea ,&nbsp;Darejani Gurtchumelia ,&nbsp;Alessandra Nunes Loureiro Prezotti ,&nbsp;Luciana Correa Oliveira de Oliveira ,&nbsp;Julissa Leon ,&nbsp;Mark Fosdal ,&nbsp;Johnny Mahlangu","doi":"10.1016/j.rpth.2024.102655","DOIUrl":"10.1016/j.rpth.2024.102655","url":null,"abstract":"<div><h3>Background</h3><div>Trenonacog alfa is a recombinant factor IX approved for adolescents and adults with hemophilia B.</div></div><div><h3>Objectives</h3><div>The aim of this study was to assess the pharmacokinetics (PK), efficacy as prophylaxis, control of bleeding episodes, and safety of trenonacog alfa in previously treated participants aged &lt;12 years with severe or moderately severe hemophilia B and no current or history of inhibitors.</div></div><div><h3>Methods</h3><div>The study had 3 phases: (1) PK evaluation after a single infusion of 75 ± 5 IU/kg, (2) treatment phase in which participants received trenonacog alfa prophylaxis 35 to 75 IU/kg for 50 exposure days, and (3) a continuation phase in which prophylaxis could be administered for ≥50 additional exposure days.</div></div><div><h3>Results</h3><div>The PK of trenonacog alfa was comparable between adolescents and adults except for higher clearance, shorter mean residence time and elimination half-life, and lower incremental recovery. Prophylaxis resulted in a median annualized bleeding rate of 0.86 (mean = 2.34) for the combined treatment and continuation phases; 33.3% of participants had zero bleeds; and 83.7% of bleeds treated resolved with 1 or 2 infusions. One adverse event was possibly related to trenonacog alfa, a nonserious hypersensitivity reaction leading to early study termination. The efficacy and safety of trenonacog alfa for prophylaxis and bleeding treatment in previously treated pediatric participants were consistent with those reported for adults and adolescents. There appeared to be no clinically important differences between the results for participants aged &lt;6 years and those aged 6 to &lt;12 years.</div></div><div><h3>Conclusion</h3><div>Trenonacog alfa is a suitable option for the management of pediatric persons with hemophilia B.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":"9 1","pages":"Article 102655"},"PeriodicalIF":3.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}